As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.
In the Kras plus checkpoint inhibitor race it looks like advantage Mirati, for now.
The $3.7bn price is cheaper than it would have been last year, but Tavneos must still fulfill its pipeline-in-a-product potential.
Getting the Swiss firm’s Beigene-derived anti-PD-1 MAb across the US finish line is proving harder than expected.
Failure of the company’s in-house lead raises questions about the viability of its extensively partnered probody technology.
Yesterday’s takeout of Teneotwo came amid notable big pharma interest in the geeky science behind heavy chain-only antibodies.
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
DLL3, a pariah antigen after the implosion of Abbvie’s Rova-T, holds the interest of a handful of industry players.